Japan’s pharmaceutical industry is undergoing a period of transformation, and the contract development and manufacturing organization (CDMO) of large molecule active pharmaceutical ingredients (APIs) ...

Japan is legendary for its focus—many would say obsession—on producing high-quality products. When it comes to sourcing active pharmaceutical ingredients (APIs), Japanese generic drug firms are ...

Ames Gross shares his insights into the opportunities in Japan's API market in his latest article. Asia's active pharmaceutical ingredient (API) market is growing at a rapid pace. From 2008 to 2012, ...

The increase in the development of new drugs in Japan which will create opportunities for both international partners and domestic manufacturers of active pharmaceutical ingredients (APIs ) and ...

Japan's government is looking to procure more generic drugs to help relieve its healthcare budget, and Eisai intends to cash in on that shift by offering its own India-made APIs to competitors. It is ...

Daiichi Sankyo will close an active pharmaceutical ingredients (API) plant in Hiratsuka, Japan, by September 2017. Opened in 1962, the facility employs 150 people and is one of Daiichi Sankyo’s four ...